Is there a higher risk of rapid changes in cardiac mobility leading to arrest in a patient with cardiac involvement? Would single agent HMA first be more appropriate to minimize toxicity or is the efficacy trade-off unacceptable?

The patient is elderly, minimally symptomatic but with worsening cytopenias and declining exercise tolerance.